A Concise Synthesis of a β-Lactamase Inhibitor
- 15 September 2011
- journal article
- research article
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 13 (20), 5480-5483
- https://doi.org/10.1021/ol202195n
Abstract
MK-7655 (1) is a β-lactamase inhibitor in clinical trials as a combination therapy for the treatment of bacterial infection resistant to β-lactam antibiotics. Its unusual structural challenges have inspired a rapid synthesis featuring an iridium-catalyzed N–H insertion and a series of late stage transformations designed around the reactivity of the labile bicyclo[3.2.1]urea at the core of the target.Keywords
This publication has 19 references indexed in Scilit:
- Current Challenges in Antimicrobial ChemotherapyDrugs, 2010
- Three Decades of β-Lactamase InhibitorsClinical Microbiology Reviews, 2010
- Iridium-Catalyzed X−H Insertions of Sulfoxonium YlidesOrganic Letters, 2009
- One-Carbon Chain Extension of Esters to α-Chloroketones: A Safer Route without DiazomethaneThe Journal of Organic Chemistry, 2004
- Synthesis and biological activity of selective pipecolic acid-based TNF-α converting enzyme (TACE) inhibitorsBioorganic & Medicinal Chemistry Letters, 2002
- Reviving the Antibiotic Miracle?Science, 1994
- A novel entry to carbenoid species viaβ-ketosulfoxonium ylidesJournal of the Chemical Society, Chemical Communications, 1993
- Origin of enhanced axial attack by sterically undemanding nucleophiles on cyclohexenonesJournal of the American Chemical Society, 1987
- Electronic and conformational effects on .pi.-facial stereoselectivity in nucleophilic additions to carbonyl compoundsJournal of the American Chemical Society, 1987
- Stereochemistry of nucleophilic addition to cyclohexanone. The importance of two-electron stabilizing interactionsJournal of the American Chemical Society, 1981